Histofy, a leading UK-based pathology AI company focused on accelerating histopathology workflows in both clinical and pharmaceutical sectors, has announced a strategic partnership with Source BioScience UK Limited, the largest histopathology service provider in the United Kingdom.
This collaboration aims to accelerate the deployment of AI-driven diagnostics, improving accuracy, efficiency, and scalability of histopathological workflows.
Through this strategic investment by Source BioScience into Histofy, the two companies will explore AI-based workflow efficiencies and integration of Histofy’s cutting-edge AI technology into Source BioScience’s state-of-the-art pathology laboratories. The initiative will firstly focus on enhancing laboratory workflows and accelerating diagnostic services, with a view to scaling AI-powered diagnostics across Source BioScience’s full range of laboratory services.
Professor Nasir Rajpoot, CEO & CSO of Histofy, commented: “This is a major milestone for Histofy. Partnering with Source BioScience will enable our AI solutions to have a direct impact on patient care at scale, across one of the most trusted laboratory networks in the UK. Together, we are laying the foundation for the next generation of AI-enabled digital pathology services - ones that combine deep clinical expertise with cutting-edge artificial intelligence.”
Jay LeCoque, CEO and Executive Chairman of Source BioScience, added: “Partnering with Histofy will allow us to accelerate our AI capabilities and improve our service offering to the NHS and private healthcare providers. Our combined goal is to improve patient care by providing much needed solutions for pathologists to fully engage AI as a widely accepted cancer detection and diagnostic tool.”
The partnership will also help improve operational efficiencies and create new business opportunities through AI-enabled services and clinical trial support. It also opens the door for R&D collaborations and co-development of new AI-enabled pathology assays.